Johnson & Johnson submitted a supplemental Biologics License Application, or sBLA, to the FDA, seeking approval to include new evidence in the tremfya label for the inhibition of progression of structural damage in adults with active psoriatic arthritis, or PsA. The submission is supported by the Phase 3b APEX study in patients with active PsA, which achieved both its primary endpoint of reducing joint symptoms and its major secondary endpoint of inhibited progression of structural damage vs. placebo in bio-naive patients. Data from the APEX study were consistent with the safety profile of tremfya.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- Trump administration mulls charging patent holders 1%-5% fee, WSJ reports
- How Johnson & Johnson Stock (JNJ) Discovered a New Lease on Life
- Pacira upgraded to Buy from Hold at Truist
- Johnson & Johnson management to meet with Oppenheimer
- Halozyme says EU approves new indication for Janssen’s Darzalex Faspro